Nexsen Limited is advancing its rapid Group B Streptococcus test, StrepSure®, with a clear FDA submission timeline and early market entries across Asia-Pacific and emerging regions.
- FDA 510(k) submission targeted for Q4 2026
- Early commercialisation initiatives underway in Hong Kong, Malaysia, and India
- ISO 13485 certification expected by early Q3 2026
- Manufacturing hub established in Hong Kong for global distribution
- Clinical trials progressing in Australia and U.S. with FDA concurrence
Nexsen’s Strategic Push for StrepSure®
Nexsen Limited (ASX:NXN) has unveiled a comprehensive global rollout strategy for its rapid diagnostic test, StrepSure®, aimed at detecting Group B Streptococcus (GBS) in pregnant women. The company is targeting a U.S. Food and Drug Administration (FDA) 510(k) submission by the end of 2026, following positive pre-submission engagement that has aligned clinical and regulatory pathways.
Group B Streptococcus remains a significant cause of neonatal complications worldwide, and Nexsen’s StrepSure® promises to deliver rapid, point-of-care results within 20 to 30 minutes; dramatically faster than traditional lab-based testing. This speed could transform clinical decision-making during labour, where timely intervention is critical.
Parallel Market Entry and Manufacturing Scale-Up
While the FDA submission is a pivotal milestone, Nexsen is simultaneously advancing early market entry initiatives across Asia-Pacific and emerging markets. Hong Kong has been selected as the initial commercial launchpad, leveraging local clinical validation partnerships and serving as a gateway to China and the broader North Asia region.
In Malaysia and India, Nexsen is progressing clinical validation and regulatory registration efforts, supported by partnerships with contract manufacturers to facilitate scale-up and distribution. These efforts aim to generate early revenue streams and real-world data ahead of broader U.S. market entry.
Complementing these commercial activities, Nexsen is establishing a manufacturing and quality management infrastructure anchored in Hong Kong. The company anticipates ISO 13485 certification by early Q3 2026, enabling production capacity of approximately one million devices annually. This facility will support not only StrepSure® but also future diagnostic products, positioning Nexsen for scalable global supply.
Clinical Trials and Regulatory Progress
Clinical data collection is underway at Northern Health in Melbourne, Australia, with plans to activate U.S. clinical sites shortly. The FDA has agreed to a clinical strategy incorporating data from both Australian and U.S. sites, reflecting a robust and internationally coordinated approach. Contracts for U.S. site onboarding and clinical research organisation management are expected imminently, providing clear visibility on the path to FDA submission.
Alongside regulatory and clinical milestones, Nexsen is proactively developing reimbursement and payer strategies across multiple jurisdictions, including the U.S., to ensure alignment with healthcare payers from the outset.
Looking Ahead
StrepSure® represents the first commercial application of Nexsen’s diagnostic platform, with the potential to validate the company’s broader ambition to revolutionise rapid, point-of-care diagnostics. Beyond GBS detection, Nexsen is advancing diagnostics for kidney function, bovine mastitis, and biosecurity, targeting large markets currently underserved by slow laboratory testing.
With multiple operational, regulatory, and commercial catalysts expected over the next 6 to 12 months, Nexsen is positioning itself as a notable player in the evolving healthcare diagnostics landscape.
Bottom Line?
Nexsen’s multi-region rollout and regulatory progress set the stage for a pivotal year ahead in rapid diagnostics.
Questions in the middle?
- Will Nexsen meet its Q4 2026 FDA submission target without delays?
- How quickly can early market entries in Asia-Pacific translate into meaningful revenue?
- What reimbursement pathways will Nexsen secure to support widespread adoption in the U.S.?